MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy
MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis Suppurativa (“HS”) with MC2-32, a first-in-class, oral drug …